Radiation Boost Reduces Local Recurrence in DCIS Patients

Video

A study presented last month at ASTRO found that a boost of radiation therapy following lumpectomy in DCIS patients resulted in reduced rates of local recurrence.

A study presented last month at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston found that a boost of radiation therapy following lumpectomy in patients with ductal carcinoma in situ (DCIS) resulted in reduced rates of local recurrence.

The ipsilateral breast tumor recurrence–free survival in DCIS patients who received a radiation boost following whole breast radiation therapy experienced a reduction in local recurrence at 5 years (97.1% vs 96.3%), 10 years (94.1% vs 92.5%), and 15 years (91.6% vs 88%), with these differences achieving statistical significance (P = .013).

In this video, Meena S. Moran, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.

Recent Videos
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Related Content